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Recognizing the impact of the decision making by the dialysis access surgeon on the successful placement of autogenous
arteriovenous hemodialysis access, the Society for Vascular Surgery assembled a multispecialty panel to develop practice
guidelines in arteriovenous access placement and maintenance with the aim of maximizing the percentage and function-
ality of autogenous arteriovenous accesses that are placed. The Society commissioned the Knowledge and Encounter
Research Unit of the Mayo Clinic College of Medicine, Rochester, Minnesota, to systematically review the available
evidence in three main areas provided by the panel: timing of referral to access surgeons, type of access placed, and
effectiveness of surveillance. The panel then formulated practice guidelines in seven areas: timing of referral to the access
surgeon, operative strategies to maximize the placement of autogenous arteriovenous accesses, first choice for the
autogenous access, choice of arteriovenous access when a patient is not a suitable candidate for a forearm autogenous
access, the role of monitoring and surveillance in arteriovenous access management, conversion of a prosthetic
arteriovenous access to a secondary autogenous arteriovenous access, and management of the nonfunctional or failed
arteriovenous access. For each of the guidelines, the panel stated the recommendation or suggestion, discussed the
evidence or opinion upon which the recommendation or suggestion was made, detailed the values and preferences that
influenced the group’s decision in formulating the relevant guideline, and discussed technical remarks related to the
particular guideline. In addition, detailed information is provided on various configurations of autogenous and
prosthetic accesses and technical tips related to their placement. (J Vasc Surg 2008;48:2S-25S.)Autogenous arteriovenous (AV) access for hemodialy-
sis has been shown to be superior to prosthetic graft or
catheter access in terms of patient morbidity and mortality.
In addition, the maintenance of autogenous AV access is
less expensive than prosthetic conduits.1-5 Although several
reports have shown an autogenous AV access is feasible in
most patients in the United States, construction and utili-
zation rates for autogenous AV access for hemodialysis in
this country are dramatically lower than in Europe and
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2SJapan.6,7 Nevertheless, rates of autogenous AV access
within the United States have improved in the last several
years. This important progress likely reflects the effect of
national efforts to increase autogenous access placement,
such as the Centers for Medicare and Medicaid Services
(CMS)–sponsored AV Fistula First Breakthrough Initiative
(FFBI) and the National Kidney Foundation (NKF)-Kidney
Disease Outcomes Quality Initiative (KDOQI) Clinical Prac-
tice Guidelines,8,9 as well as improved preoperative evalua-
tion, vessel mapping, and accepted priority for autogenous
access. The development of alternative and innovative ap-
proaches to autogenous AV access construction has also
contributed to wider utilization of autogenous access in
this country.10
Ten years ago, in October 1997, the NKF-KDOQI
Clinical Practice Guidelines for Vascular Access were pub-
lished in an effort to increase the placement of autogenous
AV access and to prolong the use of existing access by
detection of, and timely intervention for, dysfunction.
These original guidelines and subsequent versions stress
proactive identification of patients with progressive kidney
disease, identification and protection of potential native
access construction sites by members of the health care
team and patients, and the development of a multifaceted
quality assurance program to detect at-risk vascular access,
track complication rates, and implement procedures that
maximize access longevity.
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AV access be constructed in at least 50% of all new renal
failure patients electing to receive hemodialysis as their
initial form of renal replacement therapy, with the expecta-
tion that ultimately, 40% of prevalent patients would be
receiving their hemodialysis through an autogenous AV
access.11 The 2006 updated KDOQI Guidelines raised this
benchmark for minimal use of autogenous access in preva-
lent hemodialysis patients to 65%.9
In June 2003, a coalition consisting of the CMS, the
End-Stage Renal Disease (ESRD) Networks, the Institute
for Healthcare Improvement (IHI), and other key provider
representatives jointly recommended adoption of a Na-
tional Vascular Access Improvement Initiative (NVAII).
The initial goal of this initiative was to increase the number
of autogenous AV accesses placed and functioning in suit-
able patients to meet or even surpass the targets set by
NKF-KDOQI guidelines.
The NVAII was originally intended to run through
2003; but because of early success in reaching the then-
KDOQI goal of 40% prevalence by August 2005, CMS
formally expanded its commitment by upgrading the initia-
tive to what CMS called the AV Fistula First Breakthrough
Initiative (FFBI), with a new goal of 66% by 2009.10 The
FFBI Work Group identified clinical and organizational
changes that could be adapted and applied locally by neph-
rologists, dialysis personnel, access surgeons, and patients
to increase the production and use of autogenous AV
access. They also identified system changes that could be
implemented at a national level to encourage the placement
of autogenous AV accesses at a higher rate than prosthetic
AV accesses and catheters, for example, reimbursement for
preoperative vessel mapping to identify adequate vessels for
use for autogenous access construction. As a result of the
efforts of the FFBI, the prevalence of autogenous access
had increased by 50%, from 32% to 49%, by January
2008.
The Society for Vascular Surgery (SVS), representing
2500 vascular surgeons, recognizes the effect of decision
making by the individual vascular access surgeon on the
construction and utilization of access for hemodialysis.
Therefore, the SVS approved and sponsored two initiatives:
(1) to develop and publish reporting standards for AV
hemodialysis access and (2) to develop practice guidelines
for AV hemodialysis access.
To accomplish the first initiative, the SVS charged a
multidisciplinary committee to develop standardized defi-
nitions related to AV access procedures, patency, and com-
plications. Standardization of terminology facilitates more
meaningful comparisons between published reports of
long-term patency and complications of AV access proce-
dures. These recommendations were published in the Jour-
nal of Vascular Surgery in 2002.12
To accomplish the second initiative, SVS assembled a
multispecialty expert panel, consisting of vascular access
surgeons and nephrologists, to develop clinical practice
guidelines for AV access placement. In an ongoing effort to
optimize the placement of autogenous AV access in pa-tients with chronic kidney disease (CKD) and ESRD, these
guidelines are directed toward AV access surgeons and
specialists (such as interventional radiologists, nephrolo-
gists, and cardiologists) as the providers whose ultimate
operative decision determines the type of access placed.
The panel’s recommendations have culminated in the fol-
lowing practice guidelines: optimal timing and indications
for referral of patients with advanced CKD, defined by a
Modification of Diet in Renal Disease (MDRD) glomerular
filtration rate (GFR) of 20 to 25 mL/min, to a vascular
access surgeon, preoperative evaluation for AV access, con-
figuration and strategies to optimize autogenous AV access
placement, assessment of functionality of AV access, and
treatment of AV access thrombosis.
To help the panel formulate its recommendations, the
SVS used the help of The Knowledge and Encounter
Research Unit (KER) of the Mayo Clinic College of Med-
icine, Rochester, Minnesota. This independent group per-
formed a systematic study of the available evidence in three
main areas provided by the panel: timing of referral to
access surgeons, type of access placed, and effectiveness of
surveillance.13-15 The panel adopted the Grading of Rec-
ommendations Assessment, Development and Evaluation
(GRADE) scheme to formulate these recommendations
because this system separates the strength of recommenda-
tions from the quality of the evidence.16 This separation
informs guideline users (eg, patients, clinicians, and policy
makers) of factors other than evidence, such as values and
preferences if applicable, and clinical and social circum-
stances that played a role in formulating these recommen-
dations.
These systematic literature reviews revealed a paucity of
high-quality evidence in this area, and many of the recom-
mendations herein are based on observational studies, un-
systematic observations, and consensus of our committee.
Nevertheless, some of these recommendations were graded
as strong (GRADE 1) because of the values and preferences
brought to bear by the committee and are explicitly de-
scribed in this article. In addition, because of the multidis-
ciplinary nature of the committee, these recommendations
reflect consensus among access surgeons and nephrolo-
gists. Although by spearheading this project the SVS aimed
to provide a structure to form the underpinning of patient
evaluation and decision making by the access surgeon, it is
important to emphasize that these recommendations are
not intended to supersede the surgeon’s final judgment
regarding the management of the individual patient.
1. CLINICAL RECOMMENDATION: Timing of
referral to AV access surgeon and timing of
placement of permanent vascular access
We recommend that patients with advanced CKD
disease (late stage 4, MDRD <20 to 25 mL/min) who
have elected hemodialysis as their choice of renal re-
placement therapy be referred to an access surgeon in
order to evaluate and plan construction of AV access
(GRADE 1 recommendation, very low-quality evi-
dence).
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tremity arterial and venous anatomy is adequate
for an autogenous AV access, such access should
be constructed as soon as possible to allow it
enough time to mature and undergo further in-
terventions that may be needed to ensure that the
access is ready to be used when dialysis is initi-
ated.
B. If a prosthetic access is to be constructed, this
should be delayed until just before the need for
dialysis.
1.1. Evidence
A systematic review of the literature demonstrated that
the evidence on the appropriate timing of referring patients
to vascular surgery is very scarce.13 Two observational
studies demonstrated that 5% of patients who were seen
by a vascular surgeon 1 month before hemodialysis was
initiated used a catheter as their first access17 and that,
compared with late access construction (1 month of
hemodialysis), early access construction (4months before
hemodialysis) was associated with lower risk of death and
sepsis, with relative risks (RRs) of 0.76 (95% confidence
interval [CI], 0.58-1.00) and 0.57 (95% CI, 0.41-0.79),
respectively.18 Introducing catheter use and sepsis into the
mortality model rendered the association nonsignificant. It
is difficult to predict the timing of hemodialysis onset in an
individual patient19; however, observations of the commit-
tee members suggest that access placement 6 months
before initiation of hemodialysis is unlikely to allow ade-
quate time for autogenous access maturation. Timely dis-
cussion and consultation could help avoid these adverse
outcomes.
In addition, according to unsystematic observations
and consensus of our committee, prosthetic AV accesses
should be placed no earlier than 3 to 6 weeks before an
anticipated need for hemodialysis in patients who are not
candidates for autogenous AV accesses. This is because the
lifespan of prosthetic accesses is limited by venous outflow
stenosis, which can develop at any time after access place-
ment, regardless of when hemodialysis is initiated through
the access. In addition, the prosthetic access only needs 3 to
6 weeks for incorporation in the surrounding tissue, and at
many centers, a prosthetic access is used 2 weeks of
placement or earlier, depending on the type of prosthetic
access. This recommendation is consistent with those of
KDOQI and the FFBI.8,9
1.2. Values and preferences
In formulating a strong recommendation despite the
very low-quality evidence, the committee placed a higher
value on avoiding harm associated with late access con-
struction and a lower value on potential harms and costs
associated with early referral and early access placement.
Early referral should encourage placement of autogenous
access; however, whether the autogenous access prevalence
rate can be increased to reach 66% by 2009, as desired by
CMS,8 is currently uncertain.1.3. Technical remarks
It is generally agreed that all new hemodialysis patients
should have the most optimal permanent vascular access
that can be successfully used at the time of initiation of
dialysis therapy. For this to happen, the patient must see a
nephrologist before initiation of dialysis to facilitate the
referral to an access surgeon, and the surgery must be
performed in enough time before dialysis initiation to allow
for maturation, revision, and repeat procedures if the first
attempt is unsuccessful.
Referral for initial vascular access placement should
ideally occur approximately 6 months in advance of the
anticipated need for dialysis. Because of the difficulty of
predicting timing of onset of hemodialysis in an individual
patient, it is recommended that referral for initial access
placement should occur when the estimated GFR (eGFR)
level drops20 to 25 mL/min/1.73 m2 (stage 4 CKD) in
a patient expected to start hemodialysis. However, referral
decisions should be individualized to reflect differences in
rates of actual and predicted decline in eGFR, in the com-
peting risk of death, and in patient preferences.
In theUnited States, most patients who start dialysis do
not have a functioning permanent vascular access (autoge-
nous or prosthetic) in place at the timedialysis is initiated, and
thus a cathetermust be used for dialysis until permanent access
is placed and ready to be used.20,21 Many patients are not
referred to a nephrologist until their kidney disease is already
quite advanced, allowing little opportunity for vascular access
placement before dialysis is initiated.17,22,23
Not surprisingly, patients who are referred to neph-
rologists before the initiation of dialysis are more likely to
undergo vascular access surgery before dialysis begins.24
More frequent utilization of nephrology care before the
initiation of dialysis also appears to be associated with a
lower risk of catheter use at the initiation of dialysis.24
Avorn et al24 found that patients referred to a nephrologist
90 days before the initiation of dialysis were approxi-
mately 40% more likely to undergo catheter placement
compared with those who were seen 90 days before the
initiation of dialysis. Frequency of nephrology care was also
important. Those who had fewer than three visits to a
nephrologist within the year before dialysis initiation were
40%more likely to have a catheter than those who had three
or more visits.24
In addition, predialysis nephrology referral is associated
with a shorter duration of catheter use after the initiation of
dialysis and with a greater likelihood of autogenous access
placement.25 Nevertheless, even among patients referred to
a nephrologist well in advance of the need for dialysis, most
start dialysis with a catheter rather than a permanent vascu-
lar access.20,22,25 Therefore, the need for CKD/pre-ESRD
programs is crucial to ensuring that patients are evaluated
early to receive the optimal renal replacement therapy and
permanent hemodialysis access (if hemodialysis is chosen).
The average maturation time of a new autogenous
access is 2 to 4 months.26-30 In addition, a patient whose
access fails to mature sufficiently to support hemodialysis
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enous access maturation or place a new vascular access, or
both. Hemodialysis patients are usually dialyzed through a
central venous catheter while this process is completed.
Catheter use is associated with bacteremia and inadequate
dialysis, which is time/use-related.31 Catheter use at initi-
ation of dialysis is also associated with higher subsequent
mortality.32-34 Furthermore, mortality is higher among
patients who receive dialyses continuously through a cath-
eter than among those who switch from a catheter to
autogenous or prosthetic permanent access.35 It should be
noted that it is unclear from these studies whether catheter
use directly causes higher mortality or whether catheter use
is a marker for other conditions and situations associated
with increased mortality risk.
In addition to central vein preservation, peripheral up-
per extremity veins should also be preserved for future
placement of permanent vascular access; therefore when-
ever possible, hand veins should be used in preference to
arm veins for phlebotomy and intravenous catheter place-
ment in patients with CKD, despite the increased discom-
fort for patients. Particular care should be taken to avoid
cannulation of the cephalic vein in the nondominant arm.
When arm veins must be used, the site should be rotated.
Percutaneous intravenous central catheters (PICCs) should
not be used in patients with evidence of renal dysfunction
until their renal status is evaluated.
Because of low rates of autogenous access placement
among incident hemodialysis patients, time required for
successful autogenous access maturation, and associations
of catheter use with adverse outcomes among hemodialysis
patients, there is ready consensus that patients with CKD
should be referred for autogenous access placement well
before the initiation of dialysis. However, scant information
is available to suggest exactly how far in advance of the need
for dialysis and when in relation to their level of renal
function and course of their CKD patients should be re-
ferred for initial AV access construction. Consequently,
although there is broad agreement among different na-
tional guidelines that timely referral for autogenous access
construction is important, specific recommendations are
opinion-based and vary considerably, as indicated by vari-
ous published guidelines around the world.8,10,11,36,37,38
Some are summarized below:
United States KDOQI guidelines.11
I. Guideline 1: Patient preparation for permanent he-
modialysis access:
1.3. Patients should have a functional permanent access at
the initiation of dialysis therapy.
● 1.3.1. A fistula should be placed at least 6 months
before the anticipated start of hemodialysis (HD)
treatments. This timing allows for access evaluation
and additional time for revision to ensure a working
fistula is available at initiation of dialysis therapy. (B)
● 1.3.2. A graft should, in most cases, be placed at least
3 to 6 weeks before the anticipated start of HD ther-apy. Some newer graft materials may be cannulated
immediately after placement. (B)
And these guidelines also stated:11
II. Clinical practice recommendations for guideline 1:
patient preparation for permanent hemodialysis access.
● 1.3. Patients with CKD stage 5 should be educated on
the risks and benefits associated with catheters and strongly
encouraged to allow the evaluation for and creation of a
fistula for long-term access when appropriate. Such discus-
sions with the patient should be initiatedmonths before the
anticipated start of dialysis therapy.
The FFBI. Referral to surgeon for evaluation for ac-
cess by stage 4 CKD (GFR 30), with placement of AVF
soon thereafter (GFR 20 to 30), or based on progression of
renal disease.8,10
British Renal Association. The following is stated
under guideline 7-Vascular Access of The British Renal
Association C:37
7.4. Patients should undergo fistula creation between 6
and 12 months before hemodialysis is expected to start to
allow time for adequate maturation of the fistula or time for
a revision procedure if the fistula fails or is inadequate for
use.
Canadian Society of Nephrology. Guidelines from
the Canadian Society of Nephrology indicate:38
A. Establish autogenous AV access when the patient has a
creatinine clearance of 15 to 20 mL/min or serum
creatinine of 300 to 500 mol/L, depending on the
size and weight of the patient.
B. Place dialysis prosthetic access at least 3 to 6 weeks
before an anticipated need for hemodialysis.
Caring for Australians with Renal Insufficiency
(CARI). Guidelines from Caring for Australians With Re-
nal Insufficiency state:36
A. All patients, and especially those with comorbid condi-
tions, should be referred to a vascular access surgeon
well in advance of the anticipated need for hemodialy-
sis. The exact timing depends on patient-related factors
and local facilities.
B. Several procedures may be required to establish access
and maturation of access may be prolonged in some
patients.
C. AV grafts should be placed only shortly before antici-
pated use.
Preoperative evaluation. Establishing functional AV
access requires careful preoperative evaluation and plan-
ning. This process starts by early identification of individu-
als with renal insufficiency for prompt surgical consultation
to select the best extremity and site for an autogenous AV
access. A very important determinant of the success of AV
access is an appropriate and detailed preoperative history
and examination, followed by vessel mapping.
Patient history specific to vascular access selection. Sev-
eral historical factors have been associated with increased
difficulty in establishing a functional AV access and partic-
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tus, peripheral vascular disease, severe congestive heart
failure, advanced age, and female gender.29,39-40 However,
recent reports have demonstrated that successful outcomes
are possible in several of these groups.41,42 All patients
should be viewed as potential candidates for autogenous
AV access construction, although some individuals with a
difficult access extremity will require more inventive or
complex access procedures.42-44 Repeated thrombotic
events may prompt screening for a hypercoagulable state.45
Several risk factors such as homocystine and factor VIII are
commonly elevated in patients with renal failure. Chronic
anticoagulation with warfarin carries significant risk in these
patients and should probably be considered only for those
individuals with a clearly defined hypercoagulable
state.46,47 Clopidogrel is frequently used in the dialysis
population. In prosthetic accesses, it was associated with a
higher rate of bleeding and no statistical improvement in
graft patency.48-50
The patient’s surgical history, such as failed access
procedures, PICCs, pacemakers, defibrillators, arterial
catheters, cardiac surgery, or trauma often play an impor-
tant role in AV access planning. Consideration of the
patient’s dominant arm or incapacitation of one extremity
from a previous stroke may influence, but not dictate, an
AV access decision. Placement of an autogenous AV access
is particularly important in patients with chronic infections,
recurrent skin diseases, and immunosuppression. Finally,
the patient’s overall medical condition, social support
structure, and life expectancy should be considered when
considering long-term vascular access.
Physical examination specific to vascular access selec-
tion. Patients with forearm eczema or extensive solar ker-
atosis and those older patients with particularly thin and
fragile skin may be better suited to upper arm autogenous
AV access. Neurologic examination should record the pres-
ence of neuropathy and describe motor or sensory abnor-
malities. Evidence of congestive heart failure, such as neck
vein distension, should be addressed and cardiac function
maximized before surgery.
Unfortunately, most individuals in the United States
begin chronic dialysis through a central venous dialysis
catheter. The site and location of these existing and previ-
ous catheters should be recorded. In addition, defibrillators
and pacemakers often use the subclavian vein and are even
more likely to be associated with clinically important central
venous stenosis or occlusion. If permanent access is planned
on the side of a previous central catheter, imaging of the
central veins may be needed because any significant steno-
ses may produce venous hypertension due to markedly
increased venous blood flow from an upper extremity AV
access.51
Arterial examination. The experienced surgeon’s ex-
amination, including identification of healthy brachial, ra-
dial, and ulnar arteries, is the single most important aspect
of arterial inflow evaluation. Palpation of healthy vessels
should find the arteries soft, easily compressible, and their
pulse equal bilaterally. The Allen’s test confirms a patentpalmar arch and is particularly important when an autoge-
nous AV access at the wrist is planned. Bilateral extremity
blood pressures should be recorded and found to be equal.
Sites of previous arterial catheters or arterial donations for
coronary artery bypass grafting should be identified; the
radial artery harvested for coronary revascularization is
identified by the characteristic longitudinal incision over
the anterior aspect of the forearm. Further investigations
are indicated if the history or physical findings suggest an
arterial inflow abnormality.
Venous examination. The venous system should be
inspected with and without a venous pressure tourniquet in
place. Outflow veins should be uninterrupted and distensi-
ble. The presence of enlarged superficial veins on the chest
wall or arm edema may suggest central venous stenosis or
occlusion. Enlarged collateral veins are pathognomonic of a
segmental venous occlusion.52 Arm diameter in obese pa-
tientsmay limit access selection or dictate the need for primary
or staged vein elevation or a transposition procedure.
Noninvasive ultrasound imaging: a critical supplement
to the clinical examination. Ultrasound venous mapping is
of critical importance in these patients, not only for identi-
fying preferred autogenous access sites but also for evalu-
ating the depth of venous structures.53 Utilization of au-
togenous veins for construction of AV access is enhanced
by the identification of clinically “buried” veins as well as
unexpected venous occlusions or stenoses.47 Some obese
individuals have deep forearm veins that are quite adequate
for dialysis if transposed or superficialized. Further, if distal
arterial inflow is inadequate and the venous system is found
adequate by ultrasound imaging, functional access can of-
ten be established by using proximal arterial inflow and
establishing retrograde forearm autogenous AV access
flow.46 Although adequate arterial inflow can usually be
determined by a clinical examination, arterial abnormalities
such as the high brachial bifurcation are relatively common,
easily identified by ultrasound examination, and may sub-
stantially affect preoperative planning; this is especially rel-
evant when considering a forearm prosthetic access site. An
inadequate arterial lumen may also adversely affect out-
come and is easily determined by combining the arterial
ultrasound examination with the venous survey.
Arterial procedural evaluations specific to vascular
access. Noninvasive evaluation. A normal clinical arterial
examination without a history suggesting inflow occlusive
disease may not require a further presurgical evaluation of
the arterial inflow. However, if arterial inflow is not clearly
normal, duplex ultrasound (DU) imaging, performed si-
multaneously with vein mapping, will aid in identifying
stenotic segments and determine arterial diameter in addi-
tion to calculation of arterial flow.54,55 Theminimal arterial
lumen diameter is important. Studies have shown both 1.5
mm and 2.0 mm to be the minimally acceptable internal
arterial diameters for successful autogenous AV access,
although 2.0 mm seems to be the more commonly ac-
cepted limit in adults.56,57
A significant number of patients are poor candidates for
a radiocephalic (wrist) AV access from either an arterial or
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sound examination found 50% of patients studied had
inadequate arterial inflow to support a radiocephalic autog-
enous AV access at the wrist. Segmental Doppler pressures
may be helpful; however, vessel calcification in diabetic
patients may preclude accurate measurement of these pres-
sures. Digital pressures, transcutaneous oximetry, and re-
sistance index measurements have also been suggested as
measures of inflow adequacy and may be helpful in selected
cases. Calculating the resistance index or simple ultrasound
observation of changes in the arterial waveform during a
clinched fist maneuver (reactive hyperemia) predicts the
vessel’s ability to accommodate the anticipated marked
increase in flow required for a successful AV access.54,59
Arteriography. Arteriography may be useful in patients
with significant peripheral vascular disease, particularly in
those individuals with suspected proximal arterial occlusive
lesions where pre-AV access interventional procedures
might both identify and treat the problem site, gaining
adequate arterial inflow for the eventual autogenous AV
access. In patients nearing dialysis, the risk of contrast-
induced nephropathymust be carefully weighed against the
need for an AV access that will mature when needed by the
time of dialysis initiation. Renal protective strategies such as
hydration, limiting contrast, or using carbon dioxide as
contrast agents minimize risk to the patient.60 Administra-
tion of bicarbonate or N-acetyl cysteine may further mod-
erate the risk of contrast-induced nephropathy.61,62 Mag-
netic resonance angiography (MRA) for preoperative
arterial vascular access evaluation has not replaced arteriog-
raphy or ultrasound imaging but may be useful and appro-
priate in selected cases. Gadoliniummay cause nephrogenic
systemic fibrosis in patients with advanced CKD or dialysis
and therefore should be used only after carefully weighing
the risks and benefits of alternative imaging studies.63
Venous procedural evaluations specific to vascular ac-
cess. Noninvasive studies. As discussed the preceding clini-
cal examination, ultrasound imaging has become the com-
mon standard in preparation for an AV access
procedure.54,64 An ultrasound scan is optimally performed
by the surgeon during the initial office visit or it may be
done by a technologist.65 Ultrasound examination discov-
ers potential autogenous AV access sites that are over-
looked by physical examination. Silva et al57 found ultra-
sound evaluation increased AV fistula construction from
14% to 63%. Ultrasound venous mapping, which is per-
formed with and without a venous pressure tourniquet in
place, evaluates vein diameter, patency, continuity, and
distensibility of the planned venous outflow conduit. Both
distensibility and venous diameter have been found to
independently predict autogenous AV access success.56,57
For the surgeon performing the operative planning,
ultrasound offers simultaneous visualization of both the
deep and superficial venous systems along with adjacent
arteries. Brief, preoperative ultrasound mapping, just be-
fore the surgical procedure, is often helpful in confirming
available vessels targeted for the procedure andmarking the
anticipated surgical site.Contrast venography. This procedure may be used for
peripheral vein mapping, particularly when ultrasound im-
aging is not available. When history or physical findings
suggest a central stenosis or occlusion, venography is supe-
rior to ultrasound imaging, offers the best opportunity to
both identify and treat these central lesions, and is relatively
safe. Asif et al66 found only one patient of 25 studied
required dialysis 4 weeks after vein mapping with low-
diluted osmolarity contrast.MRA has been reported in preoper-
ative central venous imaging but has not been shown to bemore
effective than standard venography.67 As in arterial evaluations,
MRA has been rarely used in venous AV access planning. Al-
though promising, these early reports of MRAmapping should
be considered preliminary.68-69
2. CLINICAL RECOMMENDATION: Operative
strategies to optimize the placement of autogenous
arteriovenous accesses
We recommend optimizing the placement of autog-
enous accesses using the following operative strategies:
A. AV accesses are placed as far distally in the upper
extremity as possible to preserve proximal sites for
future accesses (GRADE 1 recommendation, very
low-quality evidence).
B. When possible, autogenous AV accesses should be
considered before prosthetic arteriovenous accesses
are placed. These autogenous access configurations
should include, in order of preference, the use of
direct AV anastomosis, venous transpositions, and
translocations (GRADE 1 recommendation, very
low-quality evidence).
C. Upper extremity access sites are used first, with the
nondominant arm given preference over the dom-
inant arm only when access opportunities are equal
in both extremities (GRADE 1 recommendation,
very low-quality evidence).
D. Lower extremity and body wall access sites are used
only after all upper extremity access sites have been
exhausted (GRADE 1 recommendation, very low-
quality evidence).
2.1. Evidence
These recommendations were formulated mainly ac-
cording to unsystematic observations and consensus of our
committee because there is paucity of high-quality evidence
to support them except what is cited to support recommen-
dations 3 and 4.
2.2. Values and preferences
The operative strategies recommended by the commit-
tee place high value on optimizing patient outcomes such
as preventing death, access infection, and achieving a
longer period of time with successful dialysis. In addition,
the committee took into account patient comfort by rec-
ommending that the nondominant upper extremity be
used first when access opportunities are equal. This allows
the dialysis patient to use the dominant side to pursue
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best extremity for autogenous access should be used, re-
gardless of dominance. In recommending distal upper ex-
tremity access sites, these recommendations place high
value on the preservation of proximal veins for future access
placement.
In addition, in recommending the use of autogenous
accesses first, except as stated in recommendation 4, the
committee did not favor the use of prosthetic access despite
features that may favor its use such as higher reimburse-
ment, ready availability, and shorter time to first use. How-
ever, the committee would like to point out that in the push
to perform all autogenous AV access, substandard veins are
sometimes used for autogenous accesses, taking a long time
to mature and thereby subjecting the patient to placement
of catheters for hemodialysis. Many believe that catheters
should be avoided at all cost, even if a prosthetic AV access
is used, which makes the construction of autogenous access
desirable but not always optimal.19 In addition, the com-
mittee placed higher value on avoiding infection, arterial
steal, ischemia, and other complications known to occur
with higher frequency in association with lower extremity
access placement.
2.3. Technical remarks
Various configurations of AV accesses, autogenous and
prosthetic, are described at the end of this document. We
describe here the strategies we suggest to optimize the use
of various access sites in order to provide the hemodialysis
patient with the safest and the longest life span on hemo-
dialysis possible.
Forearm. For autogenous forearm access, use of the
cephalic vein is preferred to the basilic vein secondary to its
ease of access for dialysis, with minimal need for dissection,
long incisions, and possible need for vein transpositions.
Possible sites of arterial inflow include the entire radial
artery from the posterior branch to its junction with the
ulnar at the brachial bifurcation, and the brachial artery.
The ulnar artery is usually not the first arterial option due to
its distance from the cephalic vein.
The access is placed as distally in the forearm as possible
where a normal palpable pulse is identified to preserve more
proximal sites of inflow for future accesses. Therefore, in
patients with a palpable posterior branch of the radial artery
pulse, an autogenous posterior radial branch–cephalic di-
rect wrist access (snuffbox) should be considered. In pa-
tients with a nonpalpable posterior branch of the radial
artery pulse but a palpable radial artery pulse at the wrist, an
autogenous radial–cephalic direct wrist access is per-
formed. In either of these cases, if the cephalic vein is felt to
be too deep or is not close to the radial artery in the wrist,
an autogenous radial–cephalic forearm transposition is per-
formed. If the radial artery pulse is nonpalpable, the ulnar
may provide an alternative distal inflow site; alternatively,
the entire trunk, but especially the proximal segment of
either the radial or the ulnar artery, may provide an arterial
source. In instances where the radial or ulnar artery pulse is
not palpable at the wrist but the brachial artery pulse is, anautogenous brachial–cephalic forearm looped transposi-
tion can be performed.
When the cephalic vein is not considered adequate for
an autogenous AV access, the forearm basilic vein is the
preferred alternative. Secondary to its posteromedial loca-
tion in the forearm, a transposition is always required to
provide safe access for hemodialysis. Possible sites of arterial
inflow include the entire trunk of the radial or ulnar arteries,
or the brachial artery. Use of the posterior branch of the
radial artery is usually difficult for this procedure secondary
to the distance from the basilic vein.
Similar to the cephalic vein, the AV access is placed as
distally in the arm as possible where a palpable pulse is
identified to preserve more proximal sites of inflow for
future accesses. Therefore, when a radial artery pulse is
palpable, an autogenous radial–basilic forearm transposi-
tion is performed. If the radial artery pulse is nonpalpable
but the ulnar artery pulse is palpable, an autogenous ulnar–
basilic forearm transposition is performed. If the radial and
ulnar artery pulses are nonpalpable at the wrist, a more
proximal segment can be used if it is patent. Finally, if the
brachial artery pulse is palpable, an autogenous brachial–
basilic forearm looped transposition is performed.
When forearm autogenous accesses are exhausted, the
surgeon and patient may opt to perform a prosthetic fore-
arm access before proceeding to the upper arm to perform
an autogenous access. Of note, and as it is indicated in
Guideline 4, the committee made this one exception to the
rule of all-autogenous access. The committee suggested
that the access surgeon presents the patient with the choice
of either performing a forearm prosthetic access before
moving to the upper arm to perform an autogenous access
or placing the upper arm autogenous access primarily be-
fore placement of forearm prosthetic. Sources of arterial
inflow for forearm prosthetic AV access also include the
radial and brachial artery.
Similar to an autogenous access, the prosthetic access
should originate from an arterial inflow as distally in the arm
as possible where a normal palpable pulse is identified to
preserve more proximal arteries for future accesses. There-
fore, when the radial artery pulse is palpable and is of a good
quality, a prosthetic radial–antecubital forearm straight access
is performed. If the radial artery pulse is nonpalpable and the
brachial artery pulse is, a prosthetic brachial–antecubital
forearm loop access is performed. Care should be paid not
to cross the elbow for venous outflow to protect upper arm
veins for future autogenous access. Patients should be told
that this forearm prosthetic access is a “bridge” to an
autogenous access. The nephrologist should be informed
to minimize the number of attempts to salvage the access
with endovascular means to avoid ruining the venous out-
flow, preserving it to be used as a future autogenous access.
Upper arm. When the use of the forearm has been
exhausted, efforts at access are directed to the upper arm.
Similar to the forearm, use of the upper arm cephalic vein is
preferred to the basilic vein secondary to its lateral location
and only occasional need for extensive dissection, long
incisions, and transposition. For upper arm access, either
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inflow. Therefore, in patients with an adequate cephalic
vein and a palpable brachial artery pulse, an autogenous
brachial–cephalic upper arm direct access is performed;
alternatively, the proximal radial artery may provide a rea-
sonable alternative with less risk of steal. If the cephalic vein
is felt to be too deep or is located far from the brachial
artery, an autogenous brachial–cephalic upper arm trans-
position is performed.
When the cephalic vein is considered inadequate for an
autogenous AV access, the basilic vein in the upper arm is
the preferred alternative. Secondary to its medial and deep
location, transposition or superficialization is required for
all access using the basilic vein. In patients with an adequate
basilic vein and a palpable brachial artery pulse, an autoge-
nous brachial–basilic upper arm transposition is performed.
Alternatively, the proximal radial artery may be used as
inflow, with less risk of steal.
If the cephalic or basilic veins have been used or are not
available, an upper extremity prosthetic AV access is per-
formed. For upper arm access, the source of arterial inflow
is the brachial or proximal radial artery. If the brachial artery
is used, it must be palpable. Alternatively, or after an upper
arm prosthetic access is used, an autogenous brachial–
brachial (vein) upper arm transposition or a great saphe-
nous vein upper arm translocation may be performed. Of
note, although using the great saphenous vein is described
here as an autogenous alternative, it should be reserved as a
last-resort option because its long-term patency has not
been confirmed. Indeed, the femoral vein has been used as
an autogenous alternative with functional patency of 94%
reported at 2 years.70
Lower extremity. When use of both upper extremities
has been exhausted, lower extremity access becomes an
alternative access site. This access is less desirable secondary
to the high occurrence of lower extremity occlusive disease
in this group of patients, the higher likelihood of steal, and
the increased incidence of infections associated with groin
accesses. The great saphenous vein is the preferred conduit;
secondary to its medial and deep location, transpositions
are always required. The femoral artery (preferably the
superficial femoral artery or the profunda femoris artery) is
used for inflow and must be palpable. Therefore, for initial
lower extremity access in patients with adequate great
saphenous vein and a palpable femoral pulse, an autoge-
nous femoral–great saphenous lower extremity transposi-
tion is performed, either in a loop or straight configuration.
Alternatively, in patients with a palpable posterior or ante-
rior tibial artery pulse, either tibial artery may be used as
inflow to create an autogenous tibial–great saphenous
lower extremity direct access.
In patients without an adequate great saphenous vein,
the femoral vein (previously named superficial femoral
vein) is an appropriate alternative source of autogenous
conduit. Similar to the great saphenous vein, the femoral
vein is located too medial and deep for usable dialysis
access, and transpositions are always required. Obstructive
complications are minimized when the vein harvest is lim-ited to the anatomic segment proximal to the popliteal vein.
The femoral artery remains the source of inflow and must
be palpable. Therefore, in patients with an adequate femo-
ral vein and a palpable femoral pulse, an autogenous fem-
oral artery–femoral vein lower extremity transposition is
performed, either in straight or loop configuration.
If no lower extremity vein, including the great saphenous
or femoral, is available, a lower extremity prosthetic access is
performed. The common femoral artery can provide the
source of inflow andmust be palpable. Therefore, in a patient
with no adequate lower extremity vein and a palpable
common femoral artery pulse, a prosthetic femoral–femoral
(vein) lower extremity looped access is performed. It is
especially important to limit the size of the anastomosis (4
to 6 mm) to the femoral artery to minimize the risk of
significant steal/ischemia and potential limb threat. This is
easily accomplished by tapering the large vein to the desired
diameter with a running suture.
Body wall. After both upper and lower extremities use
has been exhausted, body wall access can be used as an
alternative access site.71 Body wall access usually requires
use of a prosthetic graft, and its use is left as a last alterna-
tive. Sources of venous outflow include the axillary, internal
jugular, and common femoral veins. The main source of
arterial inflow is the axillary artery. Appropriate options
include a prosthetic axillary–axillary (vein) chest access, a
prosthetic axillary–axillary (vein) chest loop access, a pros-
thetic axillary–internal jugular chest loop access, and a
prosthetic axillary–common femoral (vein) body wall ac-
cess. When a patient is being evaluating for placement of
AV dialysis access, this access sequencing strategy will help
the surgeon optimize the construction of autogenous ac-
cess and lengthening the time the patient can be dialyzed
safely and comfortably.
3. CLINICAL RECOMMENDATION: First choice
is forearm autogenous arteriovenous access
We recommend the placement of forearm autoge-
nous arteriovenous access as the first choice for primary
access for hemodialysis (GRADE 1 recommendation,
very low-quality evidence).
A. When arterial and venous anatomy is suitable,
placement of autogenous radial–cephalic direct
wrist access (Brescia-Cimino-Appel) or autogenous
posterior radial branch–cephalic direct wrist access
(snuffbox) is recommended.
B. In the case where arterial or venous anatomy does
not allow placement of a direct access, forearm
vein transposition or translocation are recom-
mended. These procedures should use the maxi-
mal length of adequate vein and use arterial
inflow from the forearm tailored to accommodate
this length of vein.
3.1. Evidence
Systematic review of the literature that included 83
studies revealed that, compared with prosthetic access, the
ceme
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death and access infection and with a higher primary and
secondary patency at 12 and 36 months.14 Subgroup anal-
ysis of 13 studies showed a significant access location–
complication interaction, suggesting that the benefit of
autogenous access compared with prosthetic access in
terms of lowering the incidence of the three complications
of steal, aneurysm, and hematoma is significantly more in
the case of lower arm autogenous access compared with
upper arm autogenous access, with RRs of 0.20 (95%
confidence interval [CI], 0.06-0.68) for the lower arm
autogenous subgroup and 1.29 (95% CI, 0.43-3.91) for
the upper arm autogenous subgroup (P .03 ). An overall
summary of the evidence derived from this systematic re-
view is presented in Table I. Autogenous hemodialysis
access options can be maximized by using venous transpo-
sition procedures (eg, the radial–basilic forearm transposi-
tion or the brachial–basilic upper arm transposition) when
direct arteriovenous anastomosis autogenous access op-
Table I. Summary of evidence. Question: Should autogen
chronic hemodialysis?
Qualit
Studies, No. Design Limitations Inconsis
Death (follow-up 6-60 months)
27 Observational studya Seriousb No seriou
inconsi
Access infection (follow-up 6-60 months)
43 Observational studya Seriousb Seriousd
Postoperative complications (follow-up 6-60 months)
31 Observational studya Seriousb Seriousd
Length of hospitalization related to access (follow-up 6-60 month
3 Observational studya Seriousb,f No seriou
inconsi
Access failure without interventions at 12 months
42 Observational studya Seriousb Seriousd
Access failure without interventions at 36 months
24 Observational studya Seriousb Seriousd
Access failure with interventions at 12 months
25 Observational studya Seriousb Seriousd
Access failure with interventions at 36 months
20 Observational studya Seriousb Seriousd
CI, Confidence interval; N/A, Not applicable; RR, relative risk.
aOnly three of 83 studies were randomized.
bIn many studies, the two cohorts were not similar at baseline, blinded outc
reported.
cNot all of the included studies reported this outcome; thus, outcome may
dThe proportion of heterogeneity that is not attributed to chance is 50%.
eRR 0.50.
fThe imbalance in the number of the two groups suggests that surgeons in th
prosthetic ones, implying possible lack of experience in prosthetic access plations are not available.4,57,72,733.2. Values and preferences
The recommendation for autogenous access places
high value on optimizing patient outcomes by minimizing
the risks of death and infection and maximizing durability.
Prioritization of forearm access places high value on the
preservation of proximal veins or future access placement.
This recommendation places a lower value on competing
considerations such as higher reimbursement for construc-
tion of prosthetic, availability of ready to use off-the-shelf
prosthetic grafts, and a shorter period of time for the access
to be ready for hemodialysis.
3.3. Technical remarks
Despite the lack of evidence, some helpful techniques
may encourage the maturation of the autogenous access.
Gentle flushing of the distal end of the vein with heparin-
ized saline allows for evaluation of the caliber and extent of
the vein and identification of side branches for ligation
through stab incisions after performing the anastomosis.
access or prosthetics access be used for patients with
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side branches can also be delayed to a later date and
performed only if the autogenous access does not mature in
a timely basis.
In autogenous accesses originating from arteries
proximal to the radial, the arteriotomy should be limited
to a maximum length of 4 to 6 mm, using the smaller
anastomoses for those individuals at highest risk of de-
veloping steal-induced ischemia, such as those with dia-
betes mellitus and peripheral arterial occlusive disease.
Also, the anastomosis is performed with a continuous
suture to prevent future increase of the anastomotic
surface area. These two maneuvers limit future increases
in flow through the autogenous access and decrease the
incidence of arterial steal. Although the role of exercise
to encourage early maturation of the autogenous access
is not supported by strong evidence, some access sur-
geons continue to ask patients to perform hand exercises
starting 24 to 48 hours postoperatively to increase blood




Autogenous access Prosthetic access RR (95% CI)
2729/16823 7001/31698 0.76 (0.67 to 0.86)
527/9337 656/4416 0.18 (0.11 to 0.31)
338/7122 162/3071 0.73 (0.48 to 1.16)
2373 74 NA
1849/7628 2509/5538 0.72 (0.65 to 0.80)
1410/3798 1334/2326 0.67 (0.58 to 0.78)
892/3769 778/2735 0.83 (0.70 to 0.99)
1055/2873 622/967 0.67 (0.61 to 0.74)the access.4. CLINICAL RECOMMENDATION: Choice of
arteriovenous access when a patient is not a
suitable candidate for forearm autogenous access
For patients who have exhausted all forearm veins
on both sides and, according to vein availability and
surgical expertise, are suitable candidates for either
forearm prosthetic access or upper arm access of any
type, we suggest that the surgeon offer both alterna-
tives to patients (GRADE 2, very low-quality evi-
dence).
4.1. Evidence
The systematic review by Murad et al14 identified only
2 studies that compared the autogenous upper arm access
with the prosthetic lower arm access (prosthetic looped
forearm access). One study showed that an autogenous bra-
chial–basilic fistula in the upper arm had significantly better
primary and assisted-primary patency at 12months compared
with the polytetrafluoroethylene (PTFE) group,74 and the
t
Absolute (95% CI) Quality Importance
38 fewer per 1000
(21 to 51)
QŒŒŒ (very low) Critical
86 fewer per 1000
(66 to 97)
QŒŒŒ (very low) Important
15 fewer per 1000
(13 to 34)
QŒŒŒ (very low) Important
3.81 days shorter
(–7.77 to 0.15)
QŒŒŒ (very low) Important
131 fewer per 1000
(95 to 167)
QŒŒŒ (very low) Important
174 fewer per 1000
(93 to 242)
QŒŒŒ (very low) Important
57 fewer per 1000
(6 to 102)
QŒŒŒ (very low) Important
210 fewer per 1000
(150 to 264)
QŒŒŒ (very low) Importantngs
Effecsecond study showed both accesses had similar patency at 12
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fewer complications.75 Of note, subgroup analysis by Mu-
rad et al did not demonstrate superiority of upper arm
autogenous access compared with prosthetic accesses in
terms of complications.
4.2. Values and preference
In a patient whose bilateral forearm veins have been
exhausted, the decision whether to place an upper arm
autogenous AV access before placement of forearm pros-
thetic access is a difficult one. In the effort to maximize
placement of autogenous accesses, surgeons are sometimes
performing upper arm autogenous accesses without con-
sidering whether a forearm prosthetic access might be more
appropriate. In some instances, placement of forearm pros-
thetic access before moving to an autogenous upper arm
access may prove advantageous. Although the upper arm
autogenous access may fare better compared with a forearm
prosthetic access, using these two accesses sequentially may
lead to additive benefit: This practice may help to preserve
upper arm veins for future placement of autogenous access,
may help to increase the caliber of these veins andmaximize
the success of future upper arm autogenous access, andmay
provide patients with an additional 1 to 3 years of func-
tional hemodialysis access before resorting to catheter use
or other, less studied and less desirable configurations in the
lower extremity or body wall.
4.3. Technical remarks
When forearm autogenous sites are depleted, a forearm
prosthetic access can be considered before moving to the
upper arm for placement of an autogenous access as long as
the forearm prosthetic access does not cross the elbow
when the venous anastomosis is performed. Such access
helps to develop the upper arm veins due to the increased
flow from the forearm prosthetic access, and if the venous
Table II. Summary of evidence. Question: Should access
chronic hemodialysis?e
Qualit
Studies, No. Design Limitations Incon
Access thrombosis (follow-up mean 18 months)
7 Randomized triala Seriousb No seri
incon
Access abandonment (follow-up mean 18 months)
6 Randomized triala Seriousb Seriouse
CI, Confidence interval; RR, relative risk.
aOne study was not randomized.
bMost trials lack description of allocation concealment and blinding of pat
baseline; the latter threatens maintenance of prognosis balance after random
cAccess thrombosis is a surrogate outcome for access failure, which is a pati
dConfidence intervals are wide.
eThe proportion of heterogeneity that is not attributable to chance is 50%anastomosis is kept below the elbow, upper arm veins arepreserved for future use. In addition in the case of the
prosthetic access failing or failure, care should be directed
and the staff involved in the patient’s care should be in-
formed not to involve the veins above the elbow in proce-
dures designed to maintain or re-establish patency of the
prosthetic access.
There are additional techniques that are common to all
prosthetic access placements. The tunnel should be super-
ficial enough for easy access for the dialysis staff. A 6-mm
PTFE prosthetic graft without rings is used for the conduit.
For patients at risk for ischemia, such as when the brachial
or lower extremity arteries are used for inflow, a tapered or
stepped graft should be considered for use with the smaller
end of the graft placed at the arterial end.
5. CLINICAL RECOMMENDATION: The role of
monitoring and surveillance in arteriovenous
access management
A. We recommend regular clinical monitoring (inspec-
tion, palpation, auscultation, and monitoring for
prolonged bleeding after needle withdrawal) to de-
tect access dysfunction (GRADE 1, very low-quality
evidence).
B. We suggest access flow monitoring or static dialysis
venous pressures for routine surveillance (GRADE
2, very low-quality evidence).
C. We suggest performing a Duplex ultrasound (DU)
study or contrast imaging study in accesses that
display clinical signs of dysfunction or abnormal
routine surveillance (GRADE 2, very low-quality
evidence).
5.1. Evidence
A systematic review of 12 studies, 10 of which were
randomized, demonstrated that very low-quality evidence
illance vs watchful waiting be used for patients with
ssment
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to restore patency.15 In this review, the surveillance strat-
egy of nine studies (1363 patients) was compared with
clinical monitoring, with a vascular intervention to main-
tain or restore patency provided to both groups if needed.
Surveillance, followed by intervention, led to a nonsignifi-
cant reduction of the risk of access thrombosis (RR, 0.82;
95% CI, 0.58-1.16; I2  37%) and access abandonment
(RR, 0.80; 95% CI, 0.51-1.25; I2  60%). Three studies
(207 patients) compared the effect of vascular interventions
vs observation in patients with an abnormal surveillance
result. Vascular interventions after an abnormal AV access
surveillance result led to a significant reduction of the risk of
access thrombosis (RR, 0.53; 95% CI, 0.36-0.76) and a
nonsignificant reduction of the risk of access abandonment
(RR, 0.76; 95% CI, 0.43-1.37). Table II summarizes the
quality of evidence derived from this systematic review.
It is important to recognize that the value of surveil-
lance strongly depends on the adequacy of clinical moni-
toring (physical examination and assessment of clinical
clues of access dysfunctions). Clinical monitoring by skilled
personnel was shown to have adequate diagnostic accuracy;
clinical monitoring has been reported to have positive
predictive value of 70% to 90% in prosthetic accesses and a
specificity of 90% and a sensitivity of 38% 93% in autoge-
nous accesses.76-79 Therefore, in centers with skilled per-
sonnel, surveillance may not be as beneficial and produce
marginal benefit vs clinical monitoring, as outlined above.
However, this is not the practice in the real world, wherein
physical examinations are seldom conducted and the first
indication of an underlying stenosis is often access throm-
bosis. In this situation, surveillance may be more justified.
Furthermore, although access survival was no different
in members of the group who underwent surveillance, it is
possible that their lower incidence of thrombosis may trans-
late into a reduction in access-related costs and hospitaliza-




Access surveillance Watchful waiting RR (95% CI)
90/406 92/387 0.82 (0.58 to 1.1
94/614 88/347 0.80 (0.51 to 1.2Dossabhoy et al80 and by a quality improvement projectconducted by Wijnen et al.81 In the latter study, flow
surveillance produced a 32.5% reduction in the overall cost
of access care. Savings occurred chiefly in the prosthetic
access group and resulted from reduction in the number of
invasive procedures, central catheters, and hospitalizations.
Therefore, and despite the imprecision of evidence, surveil-
lance of accesses may be justified.
5.2. Values and preferences
These recommendations place higher value on prevent-
ing access thrombosis and the associated cost, hospitaliza-
tion, morbidity, and burdens and lower values on inconve-
nience and cost of surveillance and monitoring. In
addition, considering the low costs and harms associated
with clinical monitoring, access flow, and static dialysis
venous pressure measurements, we suggested these meth-
ods for routine surveillance to detect access dysfunction,
reserving DU scans for patients with accesses that show
symptoms and signs suggestive of impending access failure.
In these patients, the benefits of imaging studies are likely
to outweigh the potential burden and cost.82,83
5.3. Technical remarks
Assessing functionality of AV access. Various meth-
ods can be used to assess the functionality of AV accesses.
They range from clinical physical evaluation to invasive
contrast procedures. This will be discussed in the section
below, which addresses available methods used to detect or
confirm access dysfunction.
Access assessment and clinical monitoring. A. Assess-
ment of the new access. Prosthetic AV accesses, such as PTFE
grafts, can be cannulated as early as 2 weeks after their
construction, provided that they have a bruit, the postop-
erative edema has resolved, and there is no evidence of
infection. However, the clinical assessment of new autoge-
nous access requires considerable experience in interpreting
visual, auditory, and tactile clues. A normal autogenous
ect
Absolute Quality Importance
43 fewer per 1000 QŒŒŒ (very low) Critical
51 fewer per 1000 QŒŒŒ (very low) Criticalings
Eff
6)
5)access has a soft pulse that is easily compressible and a
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near the anastomosis and extend along the vein outflow for
a varying distance. In addition, a normal autogenous access
collapses when the extremity is elevated. Clinical clues of a
stenosis of an autogenous AV access include the presence of
a palpable pulse at the arterial end with possible faint thrill
or complete access collapse proximally, a discontinuous
bruit, or failure to collapse with arm elevation. The physical
examination can be used to estimate access diameter, its
depth from the skin, the presence of collateral veins and the
presence of accessory veins.
If upon clinical evaluation at 4 to 6 weeks the autoge-
nous access is not clearly maturing adequately, further
investigation is warranted to identify potentially remediable
anatomic lesions. These may include a venous or arterial
stenosis, competing veins, large patent branches, or exces-
sive depth from the skin.27 The assessment may be per-
formed either by DU scanning or by an imaging study.
Several studies have demonstrated that at least 80% of
immature autogenous accesses can be salvaged after cor-
recting one or more underlying lesions.84,85 Moreover,
immature autogenous accesses with correctable anatomic
lesions that are repaired percutaneously or surgically are
much more likely to achieve suitability for dialysis com-
pared with those that do not undergo a corrective
procedure.86
A mature autogenous access requires three compo-
nents: (1) an adequate diameter to permit safe cannulation
with dialysis needles without infiltration, (2) an adequate
access flow rate to permit achieving an access blood flow of
500 mL/min,87,88 and (3) it must be sufficiently super-
ficial to permit recognition of landmarks and accurate, safe
cannulation.27 The access blood flow increases dramatically
within 24 hours of autogenous access placement and
reaches most of its maximum flow within 3 to 6 weeks.89,90
Similarly, most of the increase in access diameter is achieved
within 4 to 8 weeks of autogenous access placement.87
When the clinical examination is equivocal, a postoper-
ative DU study can be helpful. Specifically, measurement of
the vein diameter and access blood flow is useful in predict-
ing access functionality. When the vein diameter is4 mm
and the access blood flow is500 mL/min, there is a 95%
likelihood that the autogenous access will be usable for
dialysis. If the vein diameter is4mm and the access blood
flow is500mL/min, only 33% of autogenous accesses are
likely to be suitable for dialysis. If only one of the two
criteria is met, the likelihood of access success is intermedi-
ate (60% to 70%). Interestingly, the time from placement to
cannulation varies geographically: Autogenous accesses are
routinely cannulated 1 month of placement in Europe
and Japan, whereas the average time in the United States is
about 3 months.91
B. Monitoring and surveillance of an established access. The
KDOQI defines “monitoring” as including physical exam-
ination indicators such as observation, palpation, and aus-
cultation of the access, whereas “surveillance” refers to
various tests to assess access function.Physical examination of the graft by trained nephrolo-
gists or dialysis staff is very effective in identifying accesses
with clinically significant underlying stenosis. Abnormali-
ties on physical examination of the access (absent thrill,
abnormal auscultation, persistent edema of the access ex-
tremity, venous collaterals on the ipsilateral chest wall) have
a high positive predictive value for stenosis estimated at 80%
in prosthetic accesses.92-94
A number of surveillance tests have been found
useful in detecting access dysfunction. The four most
useful surveillance methods, which are described in the
KDOQI Guidelines, are (1) serial access flow measure-
ment, (2) serial measurement of static dialysis venous
pressure, (3) prepump arterial pressure, and (4) DU
scanning. Unlike clinical evaluation, most surveillance
methods require the use of specialized equipment and
trained technicians. Each of these methods has a high
positive predictive value for identifying access dysfunction
when applied to the correct setting and to the indicated
type of access (autogenous or prosthetic access, catheter). A
description of how to perform these tests can be found in
the NKF-KDOQI Clinical Practice Guidelines.9 The clini-
cal value of each test is summarized below:
1. Access blood flow measurements. Access blood flow is
the best determinant of access function. As a prosthetic
access develops progressive stenosis, access blood flow falls
progressively. A number of studies have shown that a
prosthetic access blood flow rate of600 mL/min, or one
that has decreased by25% from the previous baseline, has
a high predictive value for significant stenosis (87% to
100%).95,96 This test is most useful for autogenous AV
access, where venous pressure surveillance is less reliable.
The most common methods of measuring access flow can
be performed in 10 to 15 minutes while the patient is on
dialysis, after reversing the arterial and venous lines. The
measurement uses ultrasound dilution (Fick principle) by
measuring the rate of change in ultrasound transmission in
the venous line after infusion of a saline bolus through the
arterial line. The KDOQI Guidelines recommend monthly
measurement of access flow. It requires specialized equip-
ment and a trained technician.
2. Static venous dialysis pressure. The greatest value of
static venous dialysis pressure (VDP) is in prosthetic ac-
cesses, but is of little or no value as a surveillance tool for
autogenous accesses because of the high incidence of low-
flow etiologies proximal to the venous needle in autoge-
nous accesses where VDP is measured.
Measurement of dynamic VDP (at a low dialysis blood
flow of 200 ml/min) is a relative poor marker of autoge-
nous or prosthetic access stenosis. It is affected by multiple
factors, including the dialysis blood flow, needle diameter,
type of dialysis machine, and the patient’s blood pressure.
Better standardization can be achieved by measuring static
VDP (at zero dialysis pump blood flow). VDP needs to be
normalized for the systemic blood pressure. The ratio of
systolic VDP to systemic systolic blood pressure can be
suggestive of stenosis when the ratio of systolic VDP to
systemic systolic blood pressure is  0.4.97 Use of mean
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transducers on conventional dialysis systems) requires that
the ratio is 0.5. The use of any given static venous
pressure ratio is not a reliable indicator of stenosis, espe-
cially in autogenous access; however, the best use of static
VDP measurement is as a trending tool, where trends of
increasing VDP may be indicative of stenosis.98 It is critical
to have a well-trained technician who performs the mea-
surements in a standardized fashion and who calibrates the
transducers.
3. Prepump arterial dialysis pressure. Most dialysis ma-
chines currently in use have a pressure transducer con-
nected to the blood line on the arterial side of the blood
pump. This prepump pressure is displayed on the informa-
tion screen and indicates the ease (or difficulty) with which
blood is drawn from the access by the blood pump at any
given pump setting. This pressure is influenced by anything
that causes restriction of flow to the pump: the needle
gauge and length, the diameter and length of the blood
line, needle position in the access, and access blood flow.
After any needle or tubing problem has been checked as the
possible cause of unexpected increasingly negative arterial
dialysis pressure and corrected, inadequate access flow,
which is the most common cause of persistently elevated
prepump arterial pressure, will be the likely cause.
New autogenous accesses, which have a high incidence
of failure to mature, almost always have an access flow
problem that is on the arterial side of the venous needle and
therefore will be identified by an excessively negative arte-
rial dialysis pressure (ADP). In addition, most of the flow-
restricting lesions in dysfunctional radial–cephalic as well as
some other autogenous accesses, are likewise present on the
arterial side of the venous needle and are often identified by
increasingly negative ADPs. Therefore, routinely checking
the ADP at every dialysis session is critically important in
evaluating function in autogenous accesses, especially new
ones.
4. Duplex ultrasound imaging. DU imaging can assess
the access for both anatomic as well as flow abnormalities
that may represent significant stenosis. This test requires
measuring the peak systolic velocity (PSV) at the graft
venous anastomosis and at any other area of visual steno-
sis.99 A ratio of PSV 2.0 at the stenotic site compared
with the PSV immediately upstream is used to diagnose
stenosis, with a positive predictive value of 80% for signifi-
cant graft stenosis.87 It is possible to measure the volume
flow through the graft, but that measurement is less accu-
rate than the flow surveillance technique previously de-
scribed. In general, DU imaging requires expensive equip-
ment, a trained technician, and is not typically performed in
the dialysis unit. The increasing availability of portable
laptop based systems may alter this in the future. However,
DU imaging is currently not an easily accessible or a cost-
effective method for routine access surveillance.
Finally, abnormalities related to the dialysis session
have a 69% positive predictive value for significant stenosis.
Within this last category, the predictive value of prolonged
bleeding from the needle sites is 76%, difficulty with can-nulation is 58%, and aspiration of clots is 30%. In addition,
an unexplained decrease (0.2 U) in delivered dialysis dose
(Kt/V) on a fixed dialysis prescription has a 69% positive
predictive value for significant stenosis.
Monitoring and surveillance by access type. 1. Autoge-
nous access. The best, most feasible tools for identifying
dysfunction in autogenous access include (1) physical ex-
amination (monitoring), (2) routine measurement of pre-
pump ADP at every dialysis session, and (3) serial access
blood flow measurements. In addition, although not rec-
ommended for routine surveillance, a recirculation study
can help in select cases of autogenous access dysfunction to
confirm inadequate access flow because recirculation results
when access flow falls below dialysis blood pump demand.
This study has little value with a prosthetic access because
prosthetic accesses will usually thrombose at low flows that
do not support adequate dialysis, whereas autogenous ac-
cesses will remain patent at very low flows, thereby permit-
ting inadequate dialysis to proceed without noticeable
etiology.
2. Prosthetic access. Prosthetic access function is best
andmost feasibly followed up by (1) a physical examination
(monitoring), (2) serial access blood flow measurements,
and (3) serial static VDP measurements.
Diagnostic tests: DU scanning and imaging
studies. Although DU can be used as a diagnostic tool for
access stenosis, it has some limitations, especially for iden-
tifying lesions behind bone, as in subclavian vein stenosis. A
major advantage is that it is noninvasive. If an etiology for
access dysfunction is not identified by DU scanning, an
imaging study should be performed. A contrast imaging
studyor other imaging studies such asMRAof the access is the
gold standard for documenting stenosis. Because it is expen-
sive and invasive, it should be reserved for those patients in
whom abnormal clinical monitoring or access surveillance
has predicted a high likelihood of hemodynamically
(50%) significant stenosis. This contrast study should
include the arterial inflow, the actual access, its outflow
vein, and central vein. If a significant stenosis is detected, a
balloon angioplasty can be performed at the same sitting.
In the event that no obstructing lesion is identified, a
physiologic etiology causing low access flow is likely and
should be investigated by an access flow study.
Preemptive angioplasty associated with monitoring
and surveillance. As mentioned previously, a number of
observational studies (using historical controls) have shown
a substantial reduction in the rate of graft thrombosis after
implementing a program of stenosis monitoring or surveil-
lance with preemptive angioplasty. More recently, six ran-
domized clinical trials have evaluated the efficacy of this
approach in reducing graft thrombosis or prolonging graft
longevity. These studies have used a variety of surveillance
methods, including static dialysis venous pressures, flow
monitoring, and DU imaging. In each of these studies, the
intervention group had a substantially higher rate of pre-
emptive angioplasty. Despite that, access surveillance failed
to improve thrombosis-free graft survival or overall (cumu-
lative) graft survival in five of the six studies.76,95,100-102
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strated a reduction in graft thrombosis and an improve-
ment in access longevity.103
The randomized studies of access surveillance have
been fairly small in size (64 to 189 patients), so they may
not have been sufficiently powered to demonstrate a small
benefit of access surveillance. Taken together, however,
they suggest that the benefit of preemptive angioplasty is
modest at best. Thus, the available surveillance methods are
quite useful in detecting significant stenosis and permitting
preemptive angioplasty before the graft thrombosis. The ben-
efit is quite short-lived, however, and the injury from the
angioplasty appears to accelerate the process of restenosis.
This topic continues to generate significant debate.104,105
6. CLINICAL RECOMMENDATION: Conversion
of a prosthetic AV access to a secondary
autogenous AV access.
We suggest that a plan and protocol for eventual
conversion of forearm prosthetic access to a secondary
autogenous AV access should be put in place at the
presence of any sign of failing forearm prosthetic AV
access, or after the first failure (GRADE 2, very low-
quality evidence).
We suggest two strategies for transitioning suitable
prosthetic AV access to secondary autogenous access
before abandoning a functional prosthetic access:
A. Conversion of the prosthetic access mature outflow
vein to an autogenous access.
B. Identifying a new, remote site for autogenous ac-
cess construction in a patient where the prosthetic
access outflow vein is not deemed suitable.
6.1. Evidence
The committee found no high-quality evidence to sup-
port a strategy of converting prosthetic accesses with im-
pending failure to secondary autogenous accesses, and
these recommendations are based on very low-quality evi-
dence that consists of unsystematic observations and the
consensus of experts.
6.2. Values and preferences
In recommending a proactive approach that involves
conversion of a failing or failed prosthetic access to a
secondary autogenous access before the prosthetic access
fails, the committee placed highest value on maintaining
functional permanent access and avoiding interruption of
dialysis and the need for central venous catheter placement,
known for an associated high rate of infection and possibly
mortality.
6.3. Technical remarks
In all instances, the construction of the new autoge-
nous access should take place before abandonment of the
prosthetic one to allow for adequate time for autogenous
AV access maturity without the need for a long-term cath-
eter. This is true whether the secondary autogenous accessis constructed by conversion of the prosthetic access mature
outflow vein to an autogenous access or by identifying a
new, remote site for autogenous access construction in a
patient where the prosthetic access outflow vein is not
deemed suitable, In preparation for the procedure, the
outflow veins should be evaluated, including the central
venous circulation, for the presence of obstruction.106 The
FFBI Work Group recommends that the evaluation for
secondary autogenous access be triggered by the initial AV
graft failure and that conversion to autogenous access be
performed no later than the second graft failure. This is to
allow adequate time for AV fistula maturation without need
for a catheter.
A. Conversion of prosthetic AV access outflow vein
to an autogenous access. This strategy is predominantly
applicable to forearm AV prosthetic access because the
outflow veins are readily accessible, well located for conver-
sion to autogenous access for hemodialysis, and one or
more of the outflow veins are usually suitable as a conduit.
The outflow vein candidates in the arm are the cephalic,
basilic, and brachial veins. In situations where these veins
are not suitable, there may be an adequate vein in the
forearm that can be used as a retrograde-flow secondary
autogenous access, after disrupting one or more valves.
This is another reason why preoperative imaging to identify
all vessel options is so critical, especially in patients with few,
if any, access options available. In most patients with an
established forearm prosthetic access, one or more of the
outflow veins becomes a mature, adequate autogenous
access conduit.107,108 If an imaging study confirms that the
outflow vein is suitable, conversion of this outflow vein into
an upper arm access provides an ideal autogenous alterna-
tive that is durable and usually usable immediately, thus
obviating or minimizing the need for a catheter. A separate
imaging study is not usually necessary, because the fistulo-
gram performed for the graft failure can be used to examine
the outflow and central veins.
B. Remote secondary autogenous AV access con-
struction. This strategy involves a physical examination
and vessel mapping in a patient with a failing prosthetic
access where an imaging study has shown that a suitable
outflow vein is not available. In this situation, evaluation of
the vessels of the contralateral extremity should be per-
formed. If suitable remote vessels are identified, a secondary
autogenous AV access construction should be undertaken as
soon as feasible to avoid the need for long-term use of a
catheter when the failing access is no longer salvageable.
7. CLINICAL RECOMMENDATION: Management
of nonfunctional or failed arteriovenous access.
We suggest open surgery, endovascular means, or a
combination of both to maintain or restore patency in
AV access (GRADE 2, very low-quality evidence).
7.1. Evidence
The choice between open and endovascular interven-
tions to improve the functionality or to restore or maintain
patency in accesses that show signs of impending failure is
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dures to be moderately effective and safe. Owing to the lack
of such randomized comparison, the panel was unable to
recommend one over the other. Open thrombectomy is
successful in restoring thrombosed access function.109,110
Similarly, endovascular techniques using a combined per-
cutaneous mechanical and pharmacologic thrombectomy
are successful in restoring function in most patients. Fur-
ther, both open and endovascular interventions may add a
further average of 12 months of functionality with low
morbidity and mortality while preserving future sites of
access.111
7.2. Values and peferences
In recommending either method or a combination of
both to be used for failed or failing AV accesses, the
committee recognizes the weakness of the evidence that
may favor one method rather than the other. Because none
of these methods has been proven to have better short- or
long-term results, the committee based its recommenda-
tion on other factors that may determine outcomes. Such
factors include the experience of the surgeon, intervention-
alist, or other AV access specialist and the ability or avail-
ability of either method in a certain situation or location
where a patient presents for care.
7.3. Technical remarks
Management of nonfunctional or failed AV access
A. Access functionality. Access functionality is a very
important concept. An access can be patent but unusable
for successful hemodialysis—and thus nonfunctional—and
such an access provides no benefit to the patient. In fact, a
nonfunctional access maybe even harmful because the pa-
tient may continue to be dialyzed using percutaneous cath-
eters, with their intended complications, while waiting for
the autogenous access to dilate and mature.
An access that has failed to mature is patent but not
functional.12 Failure to mature is more frequently an issue
with autogenous AV accesses than prosthetic grafts. As
recommended by the FFBI, every new autogenous access
should be evaluated for development at 4 weeks. If the
access is not adequately maturing by four weeks or not
functional by 12 weeks (ie, access flow 500 ml/min, a
recirculation higher than 10%, or inability to cannulate), a
contrast study should be performed. Beathard et al112
demonstrated the feasibility of salvage of the early nonma-
turing autogenous accesses. Of 63 patients with inadequate
autogenous access development, the access was patent in
74.7% after 1 year by using a systematic approach for
revision that included diagnostic angiography, percutane-
ous angioplasty, and accessory vein ligation as indicated.112
Most nonfunctional autogenous accesses should therefore
be investigated and the underlying defects corrected, with
reasonable expectation of long term functionality. The
underlying defects are usually one or more of the following:
1. Access too deep. An access can be nonfunctional be-
cause it is placed too deep in an extremity such that punc-ture is difficult, inconsistent, or traumatic to the patient and
the conduit. Several approaches can be taken to correct this
problem, depending on the location and access type. When
a prosthetic graft is placed too deep, it may be possible to
divide the graft close to an anastomosis and place it in a new
tunnel. If this is not possible, an entirely new conduit must
be placed.
Because a functioning autogenous access is very valu-
able, every attempt must be made to move the vein to a
more superficial location. Typically, this involves making an
incision along the entire length of the autogenous or trans-
posed vein and retunneling the vein, often moving the
location of the arteriovenous anastomosis. Retunneling
may shorten the length of the conduit available for punc-
ture. Before embarking on an operation of this magnitude,
the access should be studied to ensure that the conduit is
free from stenoses and that an additional procedure is likely
to render the access functional.
2. Nonligated side branches. Large, patent side branches
in an autogenous access may shunt blood away from the
axial vein, thereby preventing the main trunk from dilating
sufficiently to accept dialysis cannulae and to support ade-
quate dialysis. However, before simple surgical ligation or
endoluminal coil occlusion, themain trunkmust be studied
angiographically or with DU scanning to ensure that the
side branch has not dilated secondary to a stenosis in the
main trunk increasing resistance to axial flow. Such a lesion
must be addressed before side branch obliteration. Gener-
ally, these branches must be 2 mm diameter to be con-
sidered significant and associated with a poorly maturing
axial vein.
Localization of the side branch can be achieved by
visual inspection, ultrasound scanning, or angiography.
Road mapping of the access and side branch facilitates
accurate marking of the side branch for either an endovas-
cular or surgical approach. Coil embolization and surgical
ligation are equally acceptable approaches.
3. Insufficient arterial inflow. Insufficient arterial in-
flow as a cause for nonfunctionality is much less frequent
than venous anastomotic stenoses in prosthetic AV grafts,
representing only 3% to 5% of all stenoses identified in
hemodialysis accesses.100 Stenosis at the arterial anastomo-
sis is the most common reason for inadequate arterial
inflow. Arterial anastomotic stenosis usually occurs as a
result of a technical error or neointimal hyperplasia. The
next most common location for arterial stenosis is an orifi-
cial stenosis of the subclavian artery, most commonly on
the left and caused by atherosclerosis. These can usually be
studied by retrograde puncture of the access, navigating the
diagnostic catheter retrograde into the aorta. Alternatively,
a standard transfemoral approach can be used. Stenoses
50% of the diameter of the artery that are associated with
access failure should be treated with angioplasty. Stenting
in addition to angioplasty can be used for subclavian orifi-
cial stenoses. Before management of the arterial stenosis, an
evaluation of the access viability and stratification of the risk
of the patient to undergo such procedure should be
undertaken.
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create primary autogenous accesses, there is growing con-
cern that surgeons will use “inadequate veins” to achieve
target rates of autogenous access placement. A small or
diseased vein may result in poor venous flow that can be
associated with failed maturation, early failure, and focal
areas of stenosis or dilation, or both. Definitions of vein
adequacy will be described elsewhere in this document.
However, once the autogenous access has been placed, a
policy of aggressive re-evaluation should be performed to
maintain access functionality as described in the surveil-
lance section. Revision of a functioning autogenous access
to a more proximal arterial and venous location is another
strategy to optimize use of vein segments that have ma-
tured, while excluding diseased segments.
Poor venous outflow can also be caused by early anas-
tomotic stenoses, which are technical errors, usually mani-
fest as early thrombosis, but they can also lead to nonfunc-
tionality or failure to mature in autogenous accesses. When
diagnosed7 days of access construction, surgical revision
should be performed. When such stenoses are diagnosed
later, balloon angioplasty can be performed initially. Care
must be taken when approaching the arterial anastomosis.
Arterial embolization can result from clot fragmentation or
dislodgement of the arterial plug, and intimal dissection
can occur from vessel damage caused by the wire or throm-
bectomy device.
B. Thrombosis. Thrombosis is the most common com-
plication of AV access, accounting for a major source of
morbidity, hospitalization, and cost. A thrombosed access
is not patent and nonfunctional. Access thrombosis can
occur for a variety of reasons and can be classified into
thrombosis that occurs early (perioperative, 0-30 days) and
late (30 days) in the life of an access. It is very important
to note that thrombectomy alone may not result in long-
term patency of the access if the etiology of the thrombosis
is not addressed at the same sitting or shortly thereafter.
A stenosis is usually found along the access circuit;
therefore, the key to preventing a recurrent thrombosis of
an access is complete imaging of the arterial inflow, the
access itself, and venous outflow. The venous outflow study
should include the central venous circulation because most
accesses have more than one stenosis in their circuit and
stenoses often occur centrally.113 A retrospective review
by Sofocleous et al114 found 48 complications occurred
in 579 treated thrombosed prosthetic hemodialysis ac-
cesses. Their overall technical success rate was 81%, and
primary and secondary patency rate at 6 months were 36%
and 67%, respectively. They also found that most compli-
cations encountered during percutaneous thrombolysis or
surgical thrombectomy of thrombosed prosthetic access
could be treated at the same sitting, allowing the same
access to be used for hemodialysis.114 Percutaneous exci-
mer laser-facilitated thrombus vaporization is also found to
be safe and effective for recanalization of acute and sub-
acute thrombotic occlusions of hemodialysis shunts.115
1. Early thrombosis. Early failure occurs for many of the
same reasons described above as causing nonfunctionality.In a way, early thrombosis represents the more extreme
form of failure to mature, and mechanistically, the same
underlying problems need to be evaluated in addition to
performing thrombectomy of the conduit, either by endo-
vascular or open surgical means. Insufficient arterial inflow,
poor venous outflow, and anastomotic stenosis are the
most common reasons for early access thrombosis. Addi-
tional factors may include surgical technical errors, intrinsic
coagulation state, drops in systemic blood pressure, and
poor cardiac output.
Usually, the surgeon has some idea from the initial
procedure about what might be the most likely cause of
early access failure. Depending on what is thought to be the
most likely reason for access failure, surgical re-exploration
of the access may or may not be worthwhile. For example,
a small vein that failed to dilate with a gentle intraoperative
infusion of heparinized solution or a diseased artery with
poor inflow may not be worth re-exploration. It may make
more sense to evaluate alternative sites with a view toward
placing a new access. On the other hand, a possible kink in
the vein graft or compression within the tunnel would
require prompt urgent exploration.
Strategies for revisions can range from a simple throm-
bectomy to creation of completely new proximal anasto-
moses on the donor artery or vein. Occasionally, a pre-
existing venous stenosis that was not recognized before
placement of the access can be diagnosed angiographically.
In this situation, thrombectomy alone would not be ex-
pected to result in long-term access patency if the stenosis is
not addressed.
2. Late thrombosis. Although both autogenous and
prosthetic accesses are prone to late thrombosis, the ap-
proach to late thrombosis differs substantially. Prosthetic
accesses have a much higher incidence of thrombosis and
the access-specific stenotic lesion is more predictably found
in a specific location, at the prosthetic venous anastomosis.
In contrast, in autogenous access the stenosis can be lo-
cated anywhere along the access vein used for needle punc-
ture, and multiple stenoses are often present, thus high-
lighting the importance of complete access evaluation.
Prosthetic and autogenous accesses can both be plagued by
stenoses along the venous outflow tract, including central
veins on the same side.
Although venous stenoses are far more common, the
arterial side can also develop stenoses that can result in
access thrombosis. Such lesions can be atherosclerotic in
nature and can arise anywhere in the inflow arterial circuit.
In addition, a hyperplastic stenosis can occur at the arterial
anastomosis. Therefore, evaluation of the arterial inflow
from the central arteries to the artery providing inflow to
the access is indicated if a venous etiology cannot be found
or the quality of the arterial inflow is in question.
Intimal hyperplasia. In 90% of cases, prosthetic ac-
cesses failure is due to stenosis of the venous anastomosis,
draining vein, or central vein.115-119 Histologic analysis of
the venous anastomotic lesion demonstrates that it is iden-
tical to restenotic lesions that occur in the coronary arteries
after coronary angioplasty or artery-to-artery bypass. The
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neointimal hyperplasia at the venous anastomosis.
It is important to note that once access occlusion
occurs, prolonged patency is unusual. Thrombectomy, ac-
cess revision, or percutaneous transluminal angioplasty
usually result in a limited period of patency before failure
recurs. The inability to prolong access patency after occlu-
sion reflects several challenges, including the difficulty of
correcting the primary lesion responsible for access failure,
alteration in graft thrombogenicity, persistence of second-
ary lesions, or a combination of these factors. Moreover,
the injury caused by angioplasty of the stenotic lesion can
itself promote accelerated neointimal hyperplasia. Because
the venous anastomotic lesion of an AV graft is a prolifer-
ative vascular lesion, it is difficult to dilate and has a very
high recurrence rate, regardless of the corrective interven-
tion performed.
The KDOQIGuidelines recommend9,120 that stenoses
in prosthetic or autogenous accesses should be treated
prophylactically with percutaneous transluminal angio-
plasty or surgical revision if the stenosis is 50% of the
lumen diameter and is associated with clinical/physiologic
abnormalities.
Management of thrombosed access. The mainstay of the
management of thrombosed access is clot management,
identification of stenotic lesions causing thrombosis, and
management of significant stenotic lesions. Clot manage-
ment alone is usually not sufficient for long-term patency
unless the inciting factor is transient, such as access
compression or an episode of hypotension. Management
of thrombosed access can be by surgical or endovascular
techniques. In either method, the clot or thrombus
needs to be removed: surgically using a Fogarty balloon
catheter or by endovascular means using thrombolysis,
mechanical thrombectomy devices, or a combination
thereof. Many of these devices are currently being used;
a description of such devices can be found elsewhere in
the literature.
1. Open surgical management: After surgical catheter
thrombectomy, stenotic lesions either at the venous
outflow anastomosis of a prosthetic graft or in the main
body of the autogenous access have been traditionally
managed by open surgical techniques. If the lesion is
short, a patch angioplasty can be performed using either
autogenous venous or prosthetic material. When the
lesion is long or multiple sequential lesions are found, a
vein segment or a piece of prosthetic graft is used to
bypass the diseased segment. This bypass can be per-
formed either to replace the diseased segment or to
bypass it to a proximal healthy vein. This should be
planned in a way to keep, if possible, an incorporated
segment of a prosthetic access or a mature segment of an
autogenous access free to be continuously used for
dialysis, obviating the need for catheter placement while
the new replacement segment incorporates or matures.
This is well demonstrated when a prosthetic access
thrombosis due to a hyperplastic lesion at the graft–veininterface is being surgically repaired. A longitudinal
incision is made in the prosthetic graft and extended to
the vein through the lesion. A Fogarty catheter is used
to perform thrombectomy from the longitudinal inci-
sion. When the thrombectomy is complete, as evi-
denced by excellent arterial inflow, the longitudinal
incision is closed using a patch that widens the lumen at
the venous anastomotic site. The incorporated main
body of the access can then be used for dialysis imme-
diately after the conclusion of the procedure without the
need for percutaneous catheter placement.
2. Endovascular techniques: clot can be managed by a
variety of endovascular techniques or thrombolysis and
the stenotic lesions can also be managed using balloon
angioplasty and stenting techniques.
3. Combination of both techniques:
a. Open balloon catheter thrombectomy through a
small transverse incision remote from both the arterial
and venous anastomosis of a prosthetic access.
b. Angiographic imaging of the entire graft including
arterial anastomosis and entire venous outflow.
c. Open revision or balloon angioplasty of graft, anas-
tomotic or venous outflow tract stenoses.
ACCESS CONFIGURATIONS
Autogenous accesses
Forearm autogenous accesses. Autogenous posterior ra-
dial branch–cephalic direct wrist access (snuffbox). This au-
togenous access is performed between the end of the ce-
phalic vein and the posterior branch of the radial artery
located in the anatomic snuffbox. The cephalic vein and
radial artery are identified through a single longitudinal
incision overlying the palpable posterior branch of the
radial artery pulse. The artery is found in the base of the
snuffbox between the tendons of the extensor pollicis lon-
gus and brevis.
Autogenous radial–cephalic direct wrist access (Brescia-
Cimino-Appel).
This autogenous access is performed between the end of
the cephalic vein and the radial artery in the wrist. If the
arterial pulse and the vein are close to each other, the
procedure is performed through one longitudinal or curvi-
linear incision. If these vessels are far from each other, the
artery and the vein are dissected through two separate
longitudinal incisions and the vein is passed through a
tunnel to perform the anastomosis.
Autogenous radial–cephalic forearm transposition. This
autogenous access is performed between the end of the
cephalic vein and the radial artery in the forearm. The
cephalic vein is identified at the wrist and mobilized to the
antecubital fossa. The radial artery may be identified within
the distal portion of this incision or, if located far away, a
second longitudinal incision may be made overlying the
palpable radial artery pulse. The cephalic vein is tunneled
superficially and laterally to the radial artery to perform the
anastomosis. This operation is used in obese patients with
good inflow at the wrist and a normal cephalic vein in the
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tion if kept in its location and a direct autogenous access is
performed.
Autogenous brachial (or proximal radial)–cephalic fore-
arm looped transposition. This autogenous access is per-
formed between the end of the cephalic vein and the
brachial artery in the antecubital fossa. The cephalic vein is
identified at the wrist andmobilized to the antecubital fossa
through a single incision or multiple incisions. The brachial
or proximal radial artery is identified within the proximal
portion of this incision or, if located far away, a second
incision is made overlying the artery. The cephalic vein is
tunneled superficially in a forearm loop to the artery to
perform the anastomosis.
Autogenous radial–basilic forearm transposition. This
autogenous access is performed between the end of the
basilic vein and the radial artery in the forearm. The basilic
vein is identified in the wrist and mobilized to the antecu-
bital fossa. The radial artery is identified through a longitu-
dinal incision directly overlying the palpable radial artery
pulse. The basilic vein is tunneled superficially and laterally
to the radial artery to perform the anastomosis.
Autogenous ulnar–basilic forearm transposition. This
autogenous access is performed between the end of the
basilic vein and the ulnar artery in the forearm. The basilic
vein is identified at the wrist and mobilized to the antecu-
bital fossa. The ulnar artery is identified through a longitu-
dinal incision directly overlying the palpable ulnar artery
pulse. The basilic vein is tunneled superficially and laterally
to the ulnar artery to perform the anastomosis.
Autogenous brachial (or proximal radial)–basilic fore-
arm looped transposition. This autogenous access is per-
formed between the end of the basilic vein and the brachial
or proximal radial artery in the antecubital fossa. The basilic
vein is identified at the wrist and mobilized to the antecu-
bital fossa. The artery is identified within the proximal
portion of this incision or, if located far away, a second
longitudinal incision is made overlying the artery. The
basilic vein is tunneled superficially in a forearm loop to the
artery to perform the anastomosis.
Autogenous radial–antecubital forearm indirect greater
saphenous translocation. This autogenous access is per-
formed between the antecubital vein in the antecubital
fossa and the radial artery in the wrist using the great
saphenous vein as conduit. The antecubital vein is identi-
fied through a transverse incision in the antecubital fossa.
The radial artery is identified through a longitudinal inci-
sion overlying the palpable radial artery pulse. An appropri-
ate length of great saphenous vein is harvested from the
lower extremity. The great saphenous vein is translocated
to the forearm in a superficial and lateral tunnel between
the antecubital vein and the radial artery to perform the two
anastomoses.
Autogenous brachial (or proximal radial)–antecubital fore-
arm indirect looped greater saphenous translocation. This autog-
enous access is performed between the antecubital vein and
the brachial or proximal radial artery located in the antecu-
bital fossa using the great saphenous vein as conduit. Theantecubital vein and artery are identified through a trans-
verse incision in the antecubital fossa. An appropriate
length of great saphenous vein is harvested from the lower
extremity. The great saphenous vein is translocated to the
forearm in a looped configuration between the antecubital
vein and brachial or proximal radial artery to perform the
two anastomoses.
Upper arm autogenous accesses. Upper arm accesses
have most commonly been based on the brachial artery for
inflow; however, the proximal radial artery is an excellent
choice for inflow as long as there is adequate length of vein
to support the additional 2 to 3 cm of length required to
perform the anastomosis at the proximal radial artery,
which is a few centimeters distal to the brachial artery at the
antecubital fossa. Although confusion may arise regarding
classification of accesses originating from the proximal ra-
dial artery, these accesses should be classified as upper arm
accesses except in cases where all access flow is retrograde
into the forearm.
Autogenous brachial (or proximal radial)–cephalic up-
per arm direct access. This autogenous access is performed
between the end of the cephalic vein and the brachial or
proximal radial artery located in the antecubital fossa. If the
cephalic vein and selected artery are close together, the
procedure is performed through one transverse incision; if
not, separate incisions are made and the end of the cephalic
vein is tunneled to the brachial or proximal radial artery to
perform the anastomosis.
Autogenous brachial (or proximal radial)–cephalic up-
per arm transposition. This autogenous access is performed
between the end of the cephalic vein and the brachial or
proximal radial artery. The cephalic vein is identified at the
elbow and mobilized to an appropriate length to allow its
free end to reach the brachial artery. The brachial artery is
identified through an extension of this incision or, if located
far away, through a second incision overlying the palpable
brachial artery pulse just beyond to the proximal radial artery.
The cephalic vein is tunneled superficially and medially to-
wards the brachial artery to perform the anastomosis.
Autogenous brachial (or proximal radial)–basilic upper
arm transposition. This autogenous access is performed
between the end of the basilic vein and the brachial artery
located at or just proximal to the antecubital fossa, or the
proximal radial artery just distal to the fossa. An appropriate
length of adequate basilic vein is completely mobilized
distal to the antecubital crease if possible. The artery is
identified in the distal portion of the incision or, if located
far away, through a second incision overlying the artery.
The basilic vein is tunneled superficially and laterally to the
artery to perform the anastomosis. It is of note that this
transposition as well as others can be performed by one-
stage or two-stage techniques. A two-stage technique can
be used when the vein to be transposed has a small caliber
(4 mm), where simply anastomosing the end of the vein
to the artery would allow the vein to dilate before its
transposition in the second stage of the two-stage tech-
nique.121 Before the second stage is performed, DU study
of the vein can confirm its adequacy. The second stage is
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quately dilated, displays no stenosis, and has adequate flow
volume.121
Autogenous brachial (or proximal radial artery)–brachial
vein upper arm transposition. This autogenous access is per-
formed between the end of the brachial vein and the
brachial artery located in the antecubital fossa. If there is
adequate vein available distally, use of the proximal radial
artery as inflow is another option. The brachial vein and
brachial artery are identified through a longitudinal incision
in the antecubital fossa. The brachial vein is mobilized to
the axilla and tunneled superficially and laterally to the
brachial artery to perform the anastomosis. This transposi-
tion is well suited for a two-stage technique because the
vein is quite small, unless it has been arterialized from a
prior forearm access. Further, a two-stage transposition will
result in elongation of the vein during the first stage,
providing the additional vein length that is usually required
to transpose this vein to a lateral subcutaneous tunnel.
Finally, superficialization of the vein can be done if there is
inadequate length to transpose the vein, in which case the
vein should be positioned laterally under a skin flap so that
cannulation does not have to be performed through the
incision site.
Autogenous proximal radial–median antebrachial (or
cephalic) vein, bidirectional flow. This autogenous access is
performed as a side-to-side or end-to-side anastomosis
using the median antebrachial or cephalic vein. Retrograde
flow is established into the forearm by disruption of the first
valve under direct vision with a small probe or reverse
valvulotome. Flow into both the upper arm cephalic vein
and the forearm median antebrachial vein offers the poten-
tial for continued and uninterrupted vascular access, should
one of the outflow branches fail. The brachial artery can
also be used as inflow, but use of the proximal radial artery
minimizes the risk of steal syndrome. Further, the side-to-
side anastomosis maintains flow through multiple venous
channels.122
Autogenous brachial (proximal radial) artery–axillary
vein upper arm indirect greater saphenous translocation.
This autogenous access is performed between the axillary
vein in the axilla and the brachial or proximal radial artery in
or near the antecubital fossa using the great saphenous vein
as conduit. The axillary or proximal brachial vein is identi-
fied through a longitudinal incision in the axilla. The artery
is then isolated. An appropriate length of great saphenous
vein is harvested from the lower extremity. The great
saphenous vein is translocated in a superficial and lateral
tunnel between the axillary vein and chosen artery to per-
form the two anastomoses. The saphenous vein can also be
constructed in loop configuration in the arm or forearm.
Lower extremity autogenous accesses. Autogenous fem-
oral–great saphenous lower extremity looped transposition.
This autogenous access is performed between the end of
the great saphenous vein and the superficial femoral artery
in the groin. The great saphenous vein and common fem-
oral artery are identified through a longitudinal groin inci-
sion. The great saphenous vein is mobilized for an appro-priate length. The great saphenous vein is tunneled
superficially and laterally to the superficial femoral artery to
perform the anastomosis.
Autogenous femoral artery–femoral vein lower extremity
transposition (straight). This autogenous access is per-
formed between the end of the femoral vein and the fem-
oral artery. The femoral vein and femoral artery are identi-
fied through longitudinal incisions. The femoral vein is
mobilized for an appropriate length, usually into the ad-
ductor canal, but not including the popliteal. The femoral
vein is tunneled superficially and laterally to the femoral
artery to perform the anastomosis. In the presence of an
unacceptable distal femoral artery, the vein may be looped
back to the femoral artery in the groin.
Autogenous posterior tibial–greater saphenous lower ex-
tremity direct access. This autogenous access is performed
between the great saphenous vein and the posterior tibial
artery in the distal calf. The great saphenous vein and
posterior tibial artery are identified through a longitudinal
incision at the ankle. The distal end of the great saphenous
vein is mobilized to the posterior tibial artery to perform
the anastomosis.123
Configurations of prosthetic AV accesses
Forearm prosthetic accesses. Prosthetic radial–antecubi-
tal forearm straight access. This prosthetic access is per-
formed between the antecubital vein in the antecubital
fossa and the radial artery in the wrist using a prosthetic
graft as conduit. The antecubital vein is exposed through a
transverse incision distal to the antecubital crease. The
radial artery is exposed through a longitudinal incision in
the wrist overlying the palpable radial artery pulse. The
prosthetic graft is tunneled superficially and laterally be-
tween the antecubital vein and the radial artery to perform
the two anastomoses.
Prosthetic brachial–antecubital forearm looped access. This
prosthetic access is performed between the antecubital vein
and the brachial artery in the antecubital fossa using a
prosthetic graft as conduit. The antecubital vein and bra-
chial artery are exposed through a transverse incision in the
antecubital fossa. The prosthetic graft is tunneled superfi-
cially in a forearm loop between the antecubital vein and
the brachial artery to perform the two anastomoses.
Upper arm prosthetic accesses. Prosthetic brachial–axil-
lary (vein) upper arm access. This prosthetic access is per-
formed between the axillary or brachial vein in the axilla and
the brachial artery using a prosthetic graft as conduit. The
axillary vein is exposed through a longitudinal incision in
the axilla. The brachial artery is exposed through a longi-
tudinal incision at or just proximal to the antecubital fossa
overlying the palpable brachial artery pulse. The prosthetic
graft is tunneled superficially and laterally between the
axillary vein and the brachial artery to perform the two
anastomoses.
Lower extremity prosthetic accesses. Prosthetic femoral
artery–femoral vein lower extremity looped access. This pros-
thetic access is performed between the femoral vein and the
femoral artery using a prosthetic graft as conduit. The
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transverse incisions. The prosthetic graft is tunneled super-
ficially in a loop between the femoral vein and artery to
perform the two anastomoses.70,124
Body wall prosthetic accesses. Prosthetic axillary–axil-
lary (vein) chest access (necklace prosthetic access). This pros-
thetic access is performed between the axillary vein and the
contralateral axillary artery using a prosthetic graft as con-
duit. The axillary vein is exposed through a transverse
infraclavicular incision and is located deep to the pectoralis
major muscle. Through a similar incision, the contralateral
axillary artery is exposed. The prosthetic graft is tunneled
superficially across the chest wall between the axillary vein
and artery to perform the two anastomoses.
Prostheticaxillary–axillary(vein)chest loopaccess. This pros-
thetic access is performed between the axillary vein and the
ipsilateral axillary artery using a prosthetic graft as conduit.
The axillary vein and artery are exposed through a trans-
verse infraclavicular incision where they are located deep to
the pectoralis major muscle. The prosthetic graft is tun-
neled superficially in a loop on the chest wall between the
axillary vein and artery to perform the two anastomoses.
Prosthetic axillary–internal jugular chest loop access. This
prosthetic access is performed between the internal jugular
vein and the ipsilateral axillary artery using a prosthetic graft
as conduit. The internal jugular vein is exposed through a
longitudinal incision just anterior to the sternocleidomas-
toid muscle and is located in the carotid sheath. The axillary
artery is exposed through a transverse infraclavicular inci-
sion and is located deep to the pectoralis major muscle. The
prosthetic graft is tunneled superficially between the inter-
nal jugular vein and the axillary artery to perform the two
anastomoses.
Prosthetic axillary–femoral (vein) body wall access. This
prosthetic access is performed between the common fem-
oral vein and the axillary artery using a prosthetic graft as
conduit. The common femoral vein is exposed through a
longitudinal groin incision. The axillary artery is exposed
through a transverse infraclavicular incision and is located
deep to the pectoralis major muscle. The prosthetic graft is
tunneled superficially along the body wall between the
common femoral vein and the axillary artery to perform the
two anastomoses.
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